 A study evaluating safety and efficacy of CBM.CD19-targeted chimeric antigen receptor T cells C-CAR011 treatment in subjects with acute lymphoblastic leukemiaALL after hematopoietic stem cell transplantationHSCT. The amount of cells received:1.0-5.0×106CART cellskg 